Evidence map›Paper›PMID 34469848›Full record

ArticleNeuroImage. Clinical2021

Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study.

Michael Barnett, Niels Bergsland, Bianca Weinstock-Guttman, Helmut Butzkueven, Tomas Kalincik, Patricia Desmond, Frank Gaillard, Vincent van Pesch, Serkan Ozakbas, Juan Ignacio Rojas and 9 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in NeuroImage. Clinical, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Article
  9. Multiple Sclerosis and Autoimmune Comorbidities.Journal of personalized medicine · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 6 countries.

Michael BarnettSydney Neuroimaging Analysis Centre, Camperdown, Sydney, Australia; Brain and Mind Centre, University of Sydney, Sydney, Australia. Electronic address: michael@sydneyneurology.com.au.
Niels BergslandBuffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY, USA; IRCCS, Fondazione Don Carlo Gnocchi ONLUS, Italy.
Bianca Weinstock-GuttmanJacobs Comprehensive MS Treatment and Research Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY, USA.
Helmut ButzkuevenBox Hill Hospital, Melbourne, Australia.
Tomas KalincikCORe, Department of Medicine, The University of Melbourne, Melbourne, Australia; MS Centre, The Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia.
Patricia DesmondDepartment of Radiology, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Australia.
Frank GaillardDepartment of Radiology, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Australia.
Vincent van PeschCliniques Universitaires Saint-Luc, Brussels, UCLouvain, Belgium.
Serkan OzakbasDokuz Eylül University, Izmir, Turkey.
Juan Ignacio RojasHospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Cavit BozKTU Medical Faculty Farabi Hospital, Trabzon, Turkey.
Ayse AltintasKoç University School of Medicine, Koç University Research Center for Translational Medicine (KUTTAM), İstanbul, Turkey.
Chenyu WangSydney Neuroimaging Analysis Centre, Camperdown, Sydney, Australia; Brain and Mind Centre, University of Sydney, Sydney, Australia.
Michael G DwyerBuffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY, USA; Center for Biomedical Imaging, Clinical Translational Science Institute, USA; University at Buffalo, NY, USA.
Suzie YangSydney Neuroimaging Analysis Centre, Camperdown, Sydney, Australia.
Dejan JakimovskiBuffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY, USA.
Kain KyleSydney Neuroimaging Analysis Centre, Camperdown, Sydney, Australia; Brain and Mind Centre, University of Sydney, Sydney, Australia.
Deepa P RamasamyBuffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY, USA.
Robert ZivadinovBuffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY, USA; Center for Biomedical Imaging, Clinical Translational Science Institute, USA; University at Buffalo, NY, USA.
Buffalo Psychiatric Center · USCooperative Trials Group for Neuro-Oncology · AUUniversity of Melbourne · AUBox Hill Hospital · AUCliniques Universitaires Saint-Luc · BEDokuz Eylül University · TRFarabi Hastanesi · TRHospital Italiano de Buenos Aires · ARJacobs Institute · USKoç University · TRSouthern California Clinical and Translational Science Institute · USUniversity of Sydney · AU

Funding

University of Buffalo Clinical and Translational Science Institute - Supplement SchulyerUL1TR001412 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2015 to 2024
$33.8M
NCATS NIH HHS UL1 TR001412
6 · The paper itself

Abstract

backgroundMethodological challenges limit the use of brain atrophy and lesion burden measures in the follow-up of multiple sclerosis (MS) patients on clinical routine datasets.

objectiveTo determine the feasibility of T2-FLAIR-only measures of lateral ventricular volume (LVV) and salient central lesion volume (SCLV), as markers of disability progression (DP) in MS.

methodsA total of 3,228 MS patients from 9 MSBase centers in 5 countries were enrolled. Of those, 2,875 (218 with clinically isolated syndrome, 2,231 with relapsing-remitting and 426 with progressive disease subtype) fulfilled inclusion and exclusion criteria. Patients were scanned on either 1.5 T or 3 T MRI scanners, and 5,750 brain scans were collected at index and on average after 42.3 months at post-index. Demographic and clinical data were collected from the MSBase registry. LVV and SCLV were measured on clinical routine T2-FLAIR images.

resultsLongitudinal LVV and SCLV analyses were successful in 96% of the scans. 57% of patients had scanner-related changes over the follow-up. After correcting for age, sex, disease duration, disability, disease-modifying therapy and LVV at index, and follow-up time, MS patients with DP (n = 671) had significantly greater absolute LVV change compared to stable (n = 1,501) or disability improved (DI, n = 248) MS patients (2.0 mL vs. 1.4 mL vs. 1.1 mL, respectively, ANCOVA p < 0.001, post-hoc pair-wise DP vs. Stable p = 0.003; and DP vs. DI, p = 0.002). Similar ANCOVA model was also significant for SCLV (p = 0.03).

conclusionsLVV-based atrophy and SCLV-based lesion outcomes are feasible on clinically acquired T2-FLAIR scans in a multicenter fashion and are associated with DP over mid-term.

Indexed as

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingAtrophyBrainDisease ProgressionHumansMagnetic Resonance ImagingBrain atrophyDisability progressionLateral ventricle volumeLesion burdenMultiple sclerosisSalient central lesion volume

Identifiers

PMID34469848
PMCPMC8408519
OpenAlexW3194194298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.